葡萄膜炎藥物市場－全球產業規模、佔有率、趨勢、機會和預測，按治療類型、疾病類型、病因、配銷通路、地區和競爭細分，2020-2030 年

2024 年全球葡萄膜炎藥物市場價值為 7.053 億美元，預計在預測期內將出現令人印象深刻的成長，到 2030 年的複合年成長率為 7.20%。葡萄膜炎是指一組影響葡萄膜（眼睛的中層，包括虹膜、睫狀體和脈絡膜）的發炎性眼部疾病。如果不及時治療，葡萄膜炎會導致嚴重的視力障礙甚至失明。此病症可能是由感染、自體免疫疾病、創傷引起的，也可能是特發性的。主要症狀包括眼睛疼痛、發紅、視力模糊、光敏感和飛蚊症。隨著全球老齡人口的增加以及與年齡相關的眼部疾病變得越來越普遍，對有效的葡萄膜炎治療的需求也越來越大。治療配方的進步，加上意識的提高和診斷能力的提高，進一步支持了市場擴張。根據世界衛生組織估計，到2050年，60歲及以上人口預計將從2015年的9億增加到20億，這將增加葡萄膜炎等眼部疾病的負擔，並推動對有效藥物治療的需求。

關鍵市場促進因素

治療方案的進展

主要市場挑戰

治療費用高昂

主要市場趨勢

以患者為中心的方法

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球葡萄膜炎藥物市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依治療類型（止痛藥、抗生素、抗黴菌藥、抗病毒藥、皮質類固醇、睫狀肌麻痺劑、免疫抑制劑、單株抗體）
  • 依疾病類型（前葡萄膜炎、中間葡萄膜炎、全葡萄膜炎、後葡萄膜炎）
  • 按病因（感染性、非感染性）
  • 按配銷通路（醫院藥房、網路藥房、零售藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：亞太地區葡萄膜炎藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第7章：歐洲葡萄膜炎藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第8章：北美葡萄膜炎藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第9章：南美葡萄膜炎藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東與非洲葡萄膜炎藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 併購

第 13 章：全球葡萄膜炎藥物市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章： 大環境分析

第 16 章：競爭格局

• Allergan Inc
• Bausch & Lomb Incorporated
• Santen Pharmaceutical Co Ltd.
• AbbVie Inc.
• Novartis AG
• Eyegate Pharmaceuticals; Inc.
• Regeneron Pharmaceuticals
• Eyepoint pharmaceuticals Inc.
• Alimera Sciences Inc.

第 17 章：策略建議

第18章調查會社について,免責事項

Global Uveitis Drugs Market was valued at USD 705.30 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.20% through 2030F. Uveitis refers to a group of inflammatory eye conditions affecting the uvea, the eye's middle layer, which includes the iris, ciliary body, and choroid. If left untreated, uveitis can lead to serious vision impairment or even blindness. The condition may be caused by infections, autoimmune disorders, trauma, or may be idiopathic. Key symptoms include eye pain, redness, blurred vision, light sensitivity, and floaters. With the global aging population on the rise and age-related eye disorders becoming more prevalent, demand for effective uveitis treatments is increasing. Advances in therapeutic formulations, coupled with heightened awareness and improved diagnostic capabilities, are further supporting market expansion. According to the World Health Organization, the population aged 60 and over is expected to grow from 900 million in 2015 to 2 billion by 2050, increasing the burden of ocular diseases such as uveitis and driving the need for effective drug therapies.

Key Market Drivers

Advancements in Treatment Options

Innovative treatment modalities have significantly enhanced uveitis management in recent years. Biologics, such as adalimumab and infliximab, offer targeted therapy by modulating the immune response responsible for inflammation. Sustained-release corticosteroid implants, including dexamethasone-based options, have improved patient compliance by reducing the frequency of administration. Intravitreal injections and advanced topical formulations have gained popularity for delivering drugs directly to the affected area while minimizing systemic side effects. In March 2025, ANI Pharmaceuticals received FDA approval for an expanded indication of ILUVIEN (fluocinolone acetonide intravitreal implant) for treating chronic non-infectious uveitis of the posterior segment (NIU-PS). This move reinforces the shift toward longer-lasting, targeted therapies in uveitis treatment. These developments underscore the growing availability of effective, patient-friendly options that are helping reshape the treatment landscape for this potentially sight-threatening condition.

Key Market Challenges

High Cost of Treatment

The cost burden associated with uveitis treatment continues to be a key constraint, especially in resource-limited settings. Advanced drugs such as biologics and intravitreal implants can be expensive, often exceeding affordability thresholds for uninsured or underinsured patients. Chronic disease management requires continuous medication, regular monitoring, and specialist consultations, all of which drive long-term healthcare expenditures. In many cases, limited access to eye care professionals and diagnostic facilities compounds these challenges, particularly in rural or underserved regions. High treatment costs may result in poor adherence or delayed treatment, thereby increasing the risk of complications and irreversible vision loss. Healthcare systems also face economic strain, with the rising prevalence of uveitis increasing demand for cost-intensive care. These barriers emphasize the urgent need for affordable treatment options, including the introduction of generics and biosimilars, to improve accessibility and reduce the financial burden on patients and providers alike.

Key Market Trends

Patient-Centric Approaches

A notable trend in the uveitis drugs market is the shift toward personalized, patient-centered care. Healthcare providers are tailoring treatment strategies based on disease subtype, severity, patient health status, and individual preferences. Shared decision-making between clinicians and patients fosters better adherence and outcomes. Enhanced patient education initiatives focus on raising awareness about uveitis symptoms, treatment importance, and disease monitoring. This approach is supported by the implementation of simplified treatment regimens and reminder systems to boost adherence. Emphasis is also placed on improving quality of life through comprehensive management plans that address the physical, psychological, and social effects of the disease. Access to educational resources and patient advocacy networks is helping individuals navigate the complexities of long-term disease management, creating a more engaged and informed patient base. These strategies reflect a broader healthcare trend focused on empowering patients and optimizing long-term outcomes.

Key Market Players

• Allergan Inc.
• Bausch & Lomb Incorporated
• Santen Pharmaceutical Co. Ltd
• AbbVie Inc.
• Novartis AG
• Eyegate Pharmaceuticals Inc.
• Regeneron Pharmaceuticals
• Eyepoint Pharmaceuticals Inc.
• Alimera Sciences Inc.

Report Scope:

In this report, the Global Uveitis Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Uveitis Drugs Market, By Treatment Type:

• Analgesics
• Antibiotics
• Antifungal
• Antivirals
• Corticosteroids
• Cycloplegic Agents
• Immunosuppressant
• Monoclonal Antibodies

Uveitis Drugs Market, By Disease Type:

• Anterior Uveitis
• Intermediate Uveitis
• Panuveitis
• Posterior Uveitis

Uveitis Drugs Market, By Cause:

• Infectious
• Noninfectious

Uveitis Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Uveitis Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Uveitis Drugs Market.

Available Customizations:

Global Uveitis Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Uveitis Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Analgesics, Antibiotics, Antifungal, Antivirals, Corticosteroids, Cycloplegic Agents, Immunosuppressant, Monoclonal Antibodies)
  • 5.2.2. By Disease Type (Anterior Uveitis, Intermediate Uveitis, Panuveitis, Posterior Uveitis)
  • 5.2.3. By Cause (Infectious, Noninfectious)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Uveitis Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Cause
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Uveitis Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Cause
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. India Uveitis Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Cause
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Australia Uveitis Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Cause
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Japan Uveitis Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment Type
      • 6.3.4.2.2. By Disease Type
      • 6.3.4.2.3. By Cause
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. South Korea Uveitis Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment Type
      • 6.3.5.2.2. By Disease Type
      • 6.3.5.2.3. By Cause
      • 6.3.5.2.4. By Distribution Channel

7. Europe Uveitis Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Cause
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Uveitis Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Cause
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Uveitis Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Cause
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Spain Uveitis Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Cause
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Uveitis Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Cause
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. United Kingdom Uveitis Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Cause
      • 7.3.5.2.4. By Distribution Channel

8. North America Uveitis Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Cause
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Uveitis Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Cause
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Mexico Uveitis Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Cause
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Canada Uveitis Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Cause
      • 8.3.3.2.4. By Distribution Channel

9. South America Uveitis Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Cause
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Uveitis Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Cause
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Uveitis Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Cause
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Uveitis Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Cause
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Uveitis Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Cause
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Uveitis Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Cause
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Uveitis Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Cause
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Uveitis Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Cause
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Uveitis Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Allergan Inc
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Bausch & Lomb Incorporated
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Santen Pharmaceutical Co Ltd.
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. AbbVie Inc.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Novartis AG
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Eyegate Pharmaceuticals; Inc.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Regeneron Pharmaceuticals
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Eyepoint pharmaceuticals Inc.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Alimera Sciences Inc.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer